O.E.S.O.

• PS1 Physiology
• PS2 Pathophysiology
• PS3 Investigations
• PS4 Investigations (Cont.)
...........Symptomatology
• PS5 Extra-esophageal symptoms
...........ENT symptoms
• PS6 Pulmonary symptoms
• PS7 Histology
...........Medical Treatments

• PS8 Medical Treatments (Cont.)
.........Endoscopic Treatments
• PS9 Surgical Treatments
• PS10 Barrett's esophagus
• PS11 Distance Learning in Healthcare and Gastroenterology
Interactive, multi-disciplinary discussion on a clinical case
• PS12 Adenocarcinomas
• Closing Ceremony

•.SYMPOSIUMS

PS7 Histology

Tuesday, September 2, 2003

Presidents:H.D. APPELMAN (USA)

G.N.J. TYTGAT (The Netherlands)

2:00 p.m.

What information can be expected from biochemistry in the evaluation of inflammation-induced changes in the esophageal epithelial barrier?

P. BIANCANI (Providence)

Are there histologic changes that indicate that the refluxate is alkaline, rather than acidic?

H.D. APPELMAN (Ann Arbor)

Does DGER induce more severe histologic changes in the squamous mucosa than acid GER?

E. MONTGOMERY (Baltimore)

Is reflux gastritis a distinct histopathological entity?

G CHEJFEC (Chicago)

What is the current classification and grading of gastritis?

N. ECTORS (Leuven)

Can clinico-pathologic correlations be defined in patients with gastritis?

G. CHEJFEC (Chicago)

2:30 p.m.	Topic Forum Characteristics of so-called chemical esophagitis and gastritis. Are cardiac goblet cells a part of multifocal atrophic gastritis? E. MONTGOMERY (Baltimore) - H.D. APPELMAN (Ann Arbor) - R.H.RIDDELL (Toronto)
2:45 p.m.

Medical Treatments

2:50 p.m.

Can the effect of acid-suppressive treatment on unconjugated bile acids favor mucosal damage?

K. DVORAKOVA (Tucson)

Should increase of duodenal bicarbonate secretion by amiloride, as shown in animal models, be considered in the treatment of these patients?

S.J. KONTUREK (Krakow)

What is the effect of acid inhibition with PPIs on esophageal and gastric motility?

C. SCARPIGNATO (Parma)

3:05 p.m.
3:15 p.m.

E. KLINKENBERG KNOL (The Netherlands)

According to the limitations of pH testing in patients with chronic cough, should therapy with PPIs be systematically recommended for patients with abnormal GER?

R. HUNT (Hamilton)

Do PPIs have a significant role in the cure of ENT symptoms related to GER?

G. NARDONE (Naples)

What is the optimal PPI treatment for patients with ENT symptoms related to DGER?

M. VAEZI (Cleveland)

In patients with chronic cough, is the Symptom Association Probability Index useful to predict response to PPIs?

J.A. MURRAY (Rochester - MN)

Have these parameters been validated?

S. HARDING (Birmingham - AL)

In patients with chronic cough, are there pH parameters predictive of improvement?

B. BELTRAN (Valencia)

3:45 p.m.
3:55 p.m.

B. DUPIN-NIZARD (France)
A. PAPAZIAN (France)

3:55 p.m.

PAUSE